Best News Network

Research & Development Investments Do Not Explain Drug Price Variation

MONDAY, Oct. 3, 2022 (HealthDay News) — For a sample of 60 drugs, research and development investments do not explain the variation in list prices, according to a study published online Sept. 26 in JAMA Network Open.

Olivier J. Wouters, Ph.D., from the London School of Economics and Political Science, and colleagues conducted a cross-sectional study analyzing 60 drugs approved by the U.S. Food and Drug Administration between Jan. 1, 2009, and Dec. 31, 2018, to examine the association between treatment costs and research and development investments.

The researchers observed no association between estimated research and development investments and log-adjusted treatment costs based on list prices at launch or net prices one year after launch. When 2021 prices were used to estimate treatment costs, this result held. No association was seen between estimated research and development investments and log-adjusted treatment at launch in the fully adjusted model or from 2021 in linear regression models.

People are also reading…

“Drug companies should supply further data to support claims that high drug prices are needed to recover research and development investments, if this argument will continue to be used to justify high prices,” the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Stay connected with us on social media platform for instant update click here to join our  Twitter, & Facebook

We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.

For all the latest Health News Click Here 

 For the latest news and updates, follow us on Google News

Read original article here

Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.